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The in vitro activity of a novel 8-methoxyquinolone, BAY 12-8039, against recent clinical isolates of Strep-
tococcus pneumoniae (n 5 404), Haemophilus influenzae (n 5 330), and Moraxella catarrhalis (n 5 250) was
evaluated. Activity was compared to those of six other fluoroquinolones: ciprofloxacin, clinafloxacin, levofloxa-
cin, ofloxacin, sparfloxacin and trovafloxacin. BAY 12-8039 and clinafloxacin had the highest levels of activity
against S. pneumoniae, both with a MIC at which 90% of the isolates were inhibited (MIC90) of 0.06 mg/ml.
Trovafloxacin and sparfloxacin were the next most active agents versus S. pneumoniae (MIC90s 5 0.12 mg/ml).
No differences in activity against penicillin-susceptible, -intermediate, or -resistant strains of S. pneumoniae
were noted for any of the fluoroquinolones tested. MIC90s for the seven fluoroquinolones ranged from 0.008 to
0.06 mg/ml versus H. influenzae and from 0.008 to 0.12 mg/ml for M. catarrhalis. The MICs for two strains of
S. pneumoniae and one strain of H. influenzae were noted to be higher than those for the general population of
organisms for all of the fluoroquinolones tested. Finally, the activity of BAY 12-8039 versus S. pneumoniae was
found to be diminished when MIC determinations were performed with incubation of agar dilution plates or
broth microdilution trays in 5 to 7% CO2 versus ambient air.
The fluoroquinolones as a class of antibacterial agents first
experienced widespread clinical use during the 1980s with the
release of norfloxacin and ciprofloxacin (13). Since then, nu-
merous additional fluoroquinolones have been developed. In
general, the fluoroquinolones have proven to be effective in the
management of infections due to gram-negative bacteria (1,
25). The utility of currently available agents in treating infec-
tions caused by gram-positive organisms is questionable (21).
Streptococcus pneumoniae is of particular concern, as evi-
denced by reports of incomplete bacterial eradication and
therapeutic failure with ciprofloxacin (5, 16, 17, 20). As peni-
cillin resistance has emerged as a major problem with S. pneu-
moniae (2), effective, alternative non-b-lactam therapies have
become necessary. In this regard, the recent development of
several fluoroquinolones with extended gram-positive activity
is of interest (21).
This study was undertaken to assess the in vitro activity of
a novel 8-methoxyquinolone, BAY 12-8039 (1-cyclopropyl-
7[(S,S)-2,8-diazabicyclo[4.3.0] non-8-yl]-6-fluoro-8-methoxy-
1,4-dihydro-4-oxo-3-quinoline carboxylic acid) against S. pneu-
moniae, Haemophilus influenzae, and Moraxella catarrhalis.
Preliminary reports describing the in vitro activity of BAY
12-8039 indicate that this new agent possesses the typical ac-
tivity profile of a fluoroquinolone against gram-negative bac-
teria such as the Enterobacteriaceae and Pseudomonas, Chla-
mydia, and Mycoplasma species, in addition to having an added
spectrum of gram-positive activity (10, 12, 15, 23, 24, 26). In
this study, we compared the in vitro activity of BAY 12-8039 to
those obtained with six other quinolones, ciprofloxacin, ofloxa-
cin, levofloxacin, sparfloxacin, trovafloxacin, and clinafloxacin,
against S. pneumoniae. The latter four agents were chosen
because of their extended gram-positive activity (3, 4, 9). Be-
cause of the frequency with which S. pneumoniae is recognized
as a cause of outpatient infections that are typically treated
empirically, i.e., acute otitis media, maxillary sinusitis, acute
purulent exacerbation of chronic bronchitis, and community-
acquired pneumonia, we also assessed the activities of the
fluoroquinolones against recent clinical isolates of two other
bacteria that commonly cause these diseases, H. influenzae and
M. catarrhalis.
MATERIALS AND METHODS
Representative isolates of S. pneumoniae (n 5 404), H. influenzae (n 5 330),
and M. catarrhalis (n 5 250) were selected from a collection of clinical isolates
obtained from outpatients in 30 United States medical centers during the winter
months of 1994 to 1995 as part of a national surveillance study of antimicrobial
resistance (6–8). Broth microdilution as recommended by the National Commit-
tee for Clinical Laboratory Standards (18) was used to determine MICs. The
following media were used: S. pneumoniae, cation-adjusted Mueller-Hinton
broth (MHB) supplemented with 3% lysed horse blood; H. influenzae, hae-
mophilus test medium (14); and M. catarrhalis, MHB. The following American
Type Culture Collection control strains were used: S. pneumoniae ATCC 49619,
H. influenzae ATCC 49247, ATCC 10211, and ATCC 49766, and Escherichia coli
ATCC 25922. Antimicrobials were obtained as laboratory grade powders from
their respective manufacturers: BAY 12-8039, Bayer Corporation; ciprofloxacin,
Miles Pharmaceuticals; clinafloxacin, Parke-Davis Pharmaceutical; levofloxacin
and ofloxacin, Roussel Uclaf; sparfloxacin, Rhone-Poulenc Rorer; and trova-
floxacin, Pfizer, Inc. Isolates were stored at 270°C by using porous beads with
two subcultures made before the organisms were tested. Following inoculation
(ca. 5 3 105 CFU/ml final inoculum concentration), MIC trays were incubated at
37°C in ambient air for 24 h before examination.
RESULTS
Results of MIC determinations are listed in Table 1. BAY
12-8039 and clinafloxacin, both with a MIC at which 90% of
the isolates were inhibited (MIC90) of 0.06 mg/ml, had the
* Corresponding author. Mailing address: Clinical Microbiology
Laboratories, University of Massachusetts Medical Center, 55 Lake
Ave. North, Worcester, MA 01655. Phone: (508) 856-6417. Fax: (508)
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highest levels of activity against S. pneumoniae compared to
the other compounds. These values were twofold lower than
the MIC90s obtained with sparfloxacin and trovafloxacin and
eightfold lower than those obtained with levofloxacin, ofloxa-
cin, or ciprofloxacin. There was no difference in the overall
activity of any of the seven agents examined in this study
against penicillin-susceptible, -intermediate, or -resistant S.
pneumoniae. MIC50s and MIC90s were nearly identical for in-
dividual antimicrobials, regardless of penicillin susceptibility
category. The rank order of activity among this group of fluo-
roquinolones versus S. pneumoniae was as follows: BAY 12-
8039 5 clinafloxacin . trovafloxacin 5 sparfloxacin . levo-
floxacin . ciprofloxacin 5 ofloxacin.
Two strains of S. pneumoniae for which the MICs were
conspicuously higher than the range of MICs noted for the
general population were detected. The BAY 12-8039, clina-
floxacin, trovafloxacin, sparfloxacin, levofloxacin, ciprofloxacin,
and ofloxacin MICs for one strain were 1, 0.25, 1, 2, 4, .8, and
8 mg/ml, respectively. For the other strain, the respective MICs
were 4, 0.5, 8, 16, 16, .8, and .16 mg/ml. Excluding these two
strains, the range of MICs obtained with the seven agents
examined in this study versus all isolates of S. pneumoniae were
as follows: BAY 12-8039, #0.004 to 0.06 mg/ml; clinafloxacin,
0.015 to 0.12 mg/ml; trovafloxacin, #0.004 to 0.25 mg/ml; spar-
floxacin, 0.06–0.25 mg/ml; levofloxacin, 0.25 to 1 mg/ml; cipro-
floxacin, 0.25 to 2 mg/ml; and ofloxacin, 0.5 to 2 mg/ml. It is
possible that the two strains of S. pneumoniae for which the
fluoroquinolone MICs were uniformly higher represent resis-
tant organisms. Both of these isolates have proven to be far
more refractory to treatment with fluoroquinolones than sus-
ceptible strains in a neutropenic murine model of pneumococ-
cal lung infection (data not shown).
The effects of the MIC test format and the incubation at-
mosphere on BAY 12-8039 MICs versus S. pneumoniae were
investigated by simultaneously determining the BAY 12-8039
MICs for selected strains by agar dilution and broth microdi-
lution with plates and trays incubated in both CO2 and ambient
air. For the purpose of comparison, ciprofloxacin was also
tested in this manner. As can be seen in Table 2, CO2 incuba-
tion led to a marked increase in the MICs of BAY 12-8039 in
TABLE 1. In vitro activities of BAY 12-8039 and other fluoroquinolone antibiotics versus S. pneumoniae, H. influenzae, and M. catarrhalis
Organism
(no. of isolates)
Antimicrobial
agent
MIC (mg/ml)
50% 90% Geometric mean Range
S. pneumoniae
Penicillin susceptiblea (154) BAY 12-8039 0.03 0.06 0.04 0.015–0.06
Clinafloxacin 0.03 0.06 0.04 0.015–0.06
Trovafloxacin 0.12 0.12 0.09 0.03–0.25
Sparfloxacin 0.12 0.12 0.14 0.06–0.25
Levofloxacin 0.5 1 0.75 0.25–1
Ciprofloxacin 0.5 1 0.74 0.25–2
Ofloxacin 1 1 1.03 0.5–2
Penicillin intermediateb (150) BAY 12-8039 0.03 0.06 0.04 #0.004–4
Clinafloxacin 0.03 0.06 0.04 0.015–0.5
Trovafloxacin 0.06 0.12 0.09 #0.004–8
Sparfloxacin 0.12 0.12 0.15 0.06–16
Levofloxacin 0.5 1 0.74 0.5–16
Ciprofloxacin 1 1 0.77 0.25–.8
Ofloxacin 1 1 1.13 0.5–.16
Penicillin resistantc (100) BAY 12-8039 0.03 0.06 0.04 0.015–0.06
Clinafloxacin 0.06 0.06 0.05 0.03–0.12
Trovafloxacin 0.06 0.12 0.09 0.03–0.25
Sparfloxacin 0.12 0.12 0.14 0.06–0.25
Levofloxacin 0.5 1 0.72 0.5–1
Ciprofloxacin 1 1 0.77 0.25–2
Ofloxacin 1 1 1.02 0.5–2
H. influenzae (330) BAY 12-8039 0.03 0.06 0.04 0.008–.2
Clinafloxacin 0.004 0.008 0.006 #0.002–2
Trovafloxacin 0.015 0.03 0.02 0.004–.2
Sparfloxacin 0.015 0.015 0.01 0.004–.2
Levofloxacin 0.03 0.03 0.03 0.008–.2
Ciprofloxacin 0.03 0.03 0.03 0.008–.2
Ofloxacin 0.06 0.06 0.05 0.015–.2
M. catarrhalis (250) BAY 12-8039 0.06 0.06 0.06 0.03–0.12
Clinafloxacin 0.008 0.008 0.009 0.008–0.015
Trovafloxacin 0.008 0.015 0.008 #0.002–0.015
Sparfloxacin 0.015 0.015 0.014 0.008–0.03
Levofloxacin 0.03 0.06 0.04 0.03–0.06
Ciprofloxacin 0.008 0.015 0.007 #0.002–0.03
Ofloxacin 0.06 0.12 0.06 0.008–0.12
a Penicillin susceptible is defined by an MIC of #0.06 mg/ml.
b Penicillin intermediate is defined by an MIC of 0.12 to 1 mg/ml.
c Penicillin resistant is defined by an MIC of $2 mg/ml.
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both test formats. In addition, when the incubation atmo-
sphere was kept constant, MICs determined by agar dilution
were consistently lower than MICs determined by broth mi-
crodilution. The effects of incubation atmosphere and test for-
mat on ciprofloxacin MICs were not as pronounced.
In an attempt to understand the CO2 effect the pHs of
Mueller-Hinton agar supplemented with 5% defibrinated
sheep blood (the medium used for agar dilution tests) and
MHB plus 5% lysed horse blood (the medium used for broth
microdilution MIC determinations) were determined before
and after 24-h incubations (with and without antibiotics) in
both 5 to 7% CO2 and ambient air. The initial pH of Mueller-
Hinton sheep blood agar was 7.43 to 7.45; after incubation of
plates for 24 h in air, the pH range was 7.38 to 7.40; after
incubation for the same period in 5 to 7% CO2, the pH
dropped to 6.97 to 6.98. The same pattern was observed with
Mueller-Hinton lysed horse blood broth: initial pH, 7.56 to
7.57; pH after 24-h incubation in air, 7.60 to 7.62; pH after 24-h
incubation in 5 to 7% CO2, 6.96 to 6.98.
All seven quinolones displayed high levels of activity against
H. influenzae and M. catarrhalis (Table 1). The MIC90s ranged
from 0.008 to 0.06 mg/ml for H. influenzae and from 0.008 to
0.12 mg/ml for M. catarrhalis. However, as was the case with
two isolates of S. pneumoniae, one strain of H. influenzae
seemed to distinguish itself as perhaps being fluoroquinolone
resistant; for this strain, the MIC of clinafloxacin was 2 mg/ml
and that of the remaining antibiotics was .2 mg/ml.
DISCUSSION
We are unaware of previous published work describing the
in vitro activity of BAY 12-8039 versus large numbers of recent
clinical isolates of S. pneumoniae, H. influenzae, and M. ca-
tarrhalis. A single published study described the activity of
BAY 12-8039 versus small numbers of strains (i.e., 30 to 36) of
S. pneumoniae, H. influenzae, and M. catarrhalis taken from a
noncontemporary stock culture collection (26). In addition,
one abstract at the 1996 Interscience Conference on Antimi-
crobial Agents and Chemotherapy (ICAAC) addressed the in
vitro activity of BAY 12-8039 versus all three of these organ-
isms (12). Four others described the activity of BAY 12-8039
versus only S. pneumoniae (10, 15, 23, 24). In general, our
findings concerning the in vitro activity of BAY 12-8039 versus
H. influenzae and M. catarrhalis are consistent with the obser-
vations of previous reports (12, 26). In addition, the absolute
and relative in vitro activities of the six other fluoroquinolones
examined in this study versus S. pneumoniae, H. influenzae, and
M. catarrhalis are consistent with the observations of several
previously published investigations (3, 4, 9, 21).
Our observations regarding the in vitro activity of BAY
12-8039 versus S. pneumoniae, however, differed from those
published (26) as well as from those described at the 1996
ICAAC meeting (10, 12, 15, 23, 24). Specifically, the MIC50s
and MIC90s we obtained (i.e., 0.03 and 0.06 mg/ml, respec-
tively) were consistently two- to fourfold lower than those
previously reported. In an attempt to explain these differences,
several study strains were tested simultaneously by agar dilu-
tion in CO2, the method used by previous investigators, and by
broth microdilution with trays incubated in ambient air, as was
done in the current investigation. Consistently, two- to four-
fold-lower MICs were obtained by the latter method. Further
experimentation suggested that the noted differences might be
due to the effects of CO2 incubation of agar dilution plates.
CO2 incubation clearly produced a marked pH decrease in test
media, perhaps directly diminishing the activity of BAY 12-
8039, or perhaps altering the growth characteristics of test
strains, in turn leading to a decrease in the expression of BAY
12-8039 activity. In either case, CO2 incubation of both agar
dilution plates and broth microdilution trays resulted in ele-
vated BAY 12-8039 MICs. In addition to this CO2 effect, it was
observed that BAY 12-8039 MICs were consistently higher in
the agar dilution format than in the broth microdilution test.
Inasmuch as current National Committee for Clinical Labora-
tory Standards recommendations for quantitative susceptibility
testing of S. pneumoniae advocate the use of broth microdilu-
tion trays incubated in ambient air (18), we assert that the
generally lower MICs obtained with BAY 12-8039 versus S.
pneumoniae in the current study should be considered valid. In
view of these observations and assuming acceptable pharma-
cokinetic and toxicity profiles, clinical trials of BAY 12-8039
for the management of infections caused by the three organ-
isms noted above appear to be warranted.
The results of the current study are also notable for the
recognition of two clinical isolates of S. pneumoniae and one of
H. influenzae that appeared to be quinolone resistant. Such
strains have been described previously but infrequently (11, 19,
20). Stepwise selection of quinolone resistance in the labora-
tory has been clearly demonstrated with S. pneumoniae (19,
22). This, however, has not been demonstrable with H. influ-
enzae. Selection of ciprofloxacin-resistant strains of S. pneu-
moniae has also been observed in patients receiving this agent
(19, 20). Quinolone resistance for S. pneumoniae has been
shown in both laboratory-selected strains and clinical isolates
to be the result of primary mutations in the ParC subunit of
topoisomerase IV and secondary mutations in the GyrA sub-
unit of DNA gyrase (19). The molecular basis for quinolone
resistance in H. influenzae has not yet been elucidated. An
attempt to define the mutations responsible for the diminished
quinolone activity seen in two pneumococcal isolates and in
one strain of H. influenzae characterized in this study is in
progress.
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